Abstract
Cirrhotic cardiomyopathy is a recently recognized condition in cirrhosis consisting of systolic incompetence under condition of stress, diastolic dysfunction related to altered diastolic relaxation, and electrophysiological abnormalities in the absence of any known cardiac disease. It can be diagnosed by using a combination of electrocardiograph, 2-dimensional echocardiography, and various serum markers such as brain natriuretic factor. The underlying pathogenetic mechanisms include abnormalities in the β-adrenergic signaling pathway, altered cardiomyocyte membrane fluidity, increased myocardial fibrosis, cardiomyocyte hypertrophy, and ion channel defects. Various compounds for which levels are elevated in cirrhosis such as nitric oxide and carbon monoxide can also exert a negative inotropic effect on the myocardium, whereas excess sodium and volume retention can lead to myocardial hypertrophy. Various toxins can also aggravate the ion channel defects, thereby widening the QRS complex causing prolonged QT intervals. Clinically, systolic incompetence is most evident when cirrhotic patients are placed under stress, whether physical or pharmacological, or when the extent of peripheral arterial vasodilatation demands an increased cardiac output as in the case of bacterial infections. Acute volume overload such as immediately after insertion of a transjugular intrahepatic portosystemic shunt or after liver transplantation can also tip these cirrhotic patients into cardiac failure. Treatment of cirrhotic cardiomyopathy is unsatisfactory. There is some evidence that β-blockade may help some cirrhotic patients with baseline prolonged QT interval. Long-term aldosterone antagonism may help reduce myocardial hypertrophy. Future studies should include further elucidation of pathogenetic mechanisms so as to develop effective treatment strategies.
Similar content being viewed by others
References
Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec cirrhosis. J Clin Invest 1953;32:1025–1033
Rayes N, Bechstein WO, Keck H, Blumhardt G, Lohmann R, Neuhaus P. Causes of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralblatt Chir 1995;120:435–438
Lebrec D, Giuily N, Hadenque A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunt: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatology 1996;25:135–144
Franco D, Vons C, Traynor O, de Smadja C. Should portocaval shunt be reconsidered in the treatment of intractable ascites in cirrhosis? Arch Surg 1988;123:987–991
Laffi G, Barletta G, La Villa G, Del Bene R, Riccardi D, Ticali P, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997;113:891–898
Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The effect of cirrhotic cardiomyopathy on the cardiac response to exercise in cirrhosis. Gut 2001;49:268–275
Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, et al. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. J Hepatol 1991;12:207–216
Moreau R, Hadengue A, Soupison T, Mechin G, Assous M, Roche-Sicot J, et al. Abnormal pressor response to vasopressin in patients with cirrhosis: evidence for impaired buffering mechanism. Hepatology 1990;12:7–12
Wong F, Liu P, Lilly L, Bomzon A, Blendis L. The role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci 1999;97:259–267
Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, et al. Functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131–1137
Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, et al. Left ventricular diastolic dysfunction in liver cirrhosis. Scan J Gastroenterol 1996;31:279–284
Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. QT interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28–34
Kosar F, Ates F, Sahin I, Karincaoglu M, Yildirim B. QT interval analysis in patients with chronic liver disease: a prospective study. Angiology 2007;58:218–224
Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006;44:994–1002
Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med 1989;151:530–539
Ingles AC, Hernandez I, Garcia-Estan J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991;260:H1912–H1917
Caramelo C, Fernandez-Munoz D, Santos JC, Blanchart A, Rodriguez-Puyol D, López-Novoa JM, et al. Effect of volume expansion on hemodynamics, capillary permeability and renal function in conscious, cirrhotic rats. Hepatology 1986;6:129–134
Castro A, Jimenez W, Claria J, Ros J, Martinez JM, Bosch M, et al. Impaired responsiveness to angiotensin-II in experimental cirrhosis: role of nitric oxide. Hepatology 1993;18:367–372
Polio J, Sieber CC, Lerner E, Groszmann RJ. Cardiovascular hyporesponsiveness to norepinephrine, propranolol and nitroglycerin in portal-hypertensive and aged rats. Hepatology 1993;18:128–136
Weissler AM. Current concepts in cardiology: systolic time intervals. N Engl J Med 1977;296:321–324
Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IAD, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatology 1995;22:326–332
Sagawa K, Suga H, Shoukas A, Bakalar KM. End-systolic pressure/volume ratio: a new index of ventricular contractility. Am J Cardiol 1997;40:748–753
Lunzer MR, Newman SP, Bernard AG, Manghani KK, Sherlock SP, Ginsburg J. Impaired cardiovascular responsiveness in liver disease. Lancet 1975;2:382–385
Decaux G, Cauchie P, Soupart A, Kruger M, Delwiche F. Role of vagal neuropathy in the hyponatraemia of alcoholic cirrhosis. Br Med J 1986;293:1534–1536
Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002;36:513–520
Henriksen JH, Gotze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511–1517
La Villa G, Romanelli RG, Casini Raggi V, Tosti-Guerra C, De Feo ML, Marra F, et al. Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992;16:156–161
Wong F, Siu S, Liu P, Blendis L. Brain natriuretic peptide, is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001;101:651–657
Iwao T, Oho K, Nakano R, Sakai T, Sato M, Miyamoto Y, et al. High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis. J Hepatol 2000;32:426–433
Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients. J Gastroenterol Hepatol 2005;20:1115–1120
Bodor GS, Porter S, Landt Y, Ladenson JH. Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction. Clin Chem 1992;38:2203–2214
Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999;29:640–643
Parkes DG. Cardiovascular actions of adrenomedullin in conscious sheep. Am J Physiol 1995;268:H2574–H2578
Ikenouchi H, Kangawa K, Matsuo H, Hirata Y. Negative inotropic effects of adrenomedullin in isolated adult rabbit cardiac ventricular myocytes. Circulation 1997;95:2318–2324
Szokodi I, Kinnunen P, Tavi P, Weckstrom M, Toth M, Zruskoaho H. Evidence of adrenomedullin, a new inotropic peptide. Circulation 1998;97:1062–1070
Guevara M, Gines P, Jimenez W, Sort P, Fernandez-Esparrach G, Escorsell A, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998;114:336–343
Genesca J, Gonzalez A, Catalan R, Segura R, Martinez M, Esteban R, et al. Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis. Relationship to nitric oxide. Dig Dis Sci 1999;44:372–376
Jougasaki M, Wei CM, McKinley LJ, Burnett JCJ. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995;92:286–289
Kobayashi K, Kitamura K, Etoh T, Nagatomo Y, Takenaga M, Ishikawa T, et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 1996;131:994–998
Hirano S, Imamura T, Matsuo T, Ishiyama Y, Kato J, Kitamura K, et al. Differential responses of circulating and tissue adrenomedullin and gene expression to volume overload. J Card Fail 2000;6:120–129
Pan CS, Jin SJ, Cao CQ, Zhao J, Zhang J, Wang X, et al. The myocardial response to adrenomedullin involves increased cAMP generation as well as augmented Akt phosphorylation. Peptides 2007;28:900–909
Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 2006;111:909–927
Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008;57:268–278
Xiao RP, Cheng H, Zhou YY, Kuschel M, Lakatta EG. Recent advances in cardiac beta-adrenergic signal transduction. Circ Res 1999;85:1092–1100
Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Sem Liver Dis 2008;28:59–69
Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol 1997;26:904–912
Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology 1996;110:1191–1198
Caraceni P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. J Neuroendocrinol 2008;20(Suppl 1):47–52
Gaskari SE, Liu H, Moezi L, Li Y, Baik SK, Lee SS. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct ligated rats. Br J Pharmacol 2005;146:315–323
Batkai S, Mukhopadhyay P, Harvey-White J, Kekrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007;293:H1689–H1695
Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology 2000;118:937–944
Liu H, Song D, Lee SS. Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol Gastrointest Liver Physiol 2001;280:G68–G74
Liu H, Lee SS. Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int 2008;28:640–648
Piper RD. Myocardial dysfunction in sepsis. Clin Exp Pharmacol Physiol 1998;25:951–954
Lunseth JH, Olmstead EG, Abboud F. A study of heart disease in one hundred eight hospitalized patients dying with portal cirrhosis. Arch Intern Med 1958;102:405–413
Fields NG, Yuan B, Leenen FHH. NaCl-induced cardiac hypertrophy: cardiac sympathetic activity versus volume load. Circ Res 1991;68:745–755
Kihara M, Utagawa N, Mano Y, Horie R, Yamori Y. Biochemical aspects of salt-induced, pressure-independent left ventricular hypertrophy in rats. Heart Vessel 1985;1:212–215
Meggs LG, Ben-Ari J, Gammon D, Goodman AI. Myocardial hypertrophy: the effects of sodium and the role of sympathetic nervous activity. Am J Hypertens 1988;1:1–11
Leenen FHH, Yuan B. Dietary-sodium-induced cardiac remodeling in spontaneously hypertensive rat versus Wistar-Kyoto rat. J Hypertens 1998;16:885–892
Yoshimoto T, Hirata Y. Aldosterone as a cardiovascular risk hormone. Endocr J 2007;54:359–370
Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994;26:279–292
van Wamel AJ, Ruwhof C, van der Valk-Kokshoom LE, Schrier PI, van der Laarse A. The role of angiotensin II endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem 2001;218:113–124
Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi Y, et al. Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 1996;271:3221–3228
Schmieder RE. Salt intake is related to the process of myocardial hypertrophy in essential hypertension. JAMA 1989;262:1187–1188
Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med 2007;55:341–359
Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, et al. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol 1997;29:2893–2902
Booz GW, Dostal DE, Baker KM. Paracrine actions of cardiac fibroblasts on cardiomyocytes: implications for the cardiac renin-angiotensin system. Am J Cardiol 1999;83:44H–47H
Zierhut W, Zimmer HG. Significance of myocardial α- and β-adrenoreceptors in catecholamine induced cardiac hypertrophy. Circ Res 1989;65:1417–1425
Dostal DE, Baker KM. Angiotensin and endothelin: messengers that couple ventricular stretch to the Na+/H+ exchanger and cardiac hypertrophy. Circ Res 1998;83:870–873
Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997;273:G537–G544
Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995;22:165–172
Zhong J, Hwang TC, Adams HR, Rubin LJ. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol 1997;273:H2312–H2324
Magyar J, Iost N, Kortvely A, Banyasz T, Virag L, Szigligeti P, et al. Effects of endothelin-1 on calcium and potassium currents in undiseased human ventricular myocytes. Pflugers Arch 2000;441:144–149
Kuddus RH, Nalesnik MA, Subbotin VM, Rao AS, Gandhi CR. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes—an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol 2000;33:725–732
Gazawi H, Ljubuncic P, Cogan U, Hochgraff E, Ben-Shachar D, Bomzon A. The effects of bile acids on beta-adrenoceptors, fluidity, and the extent of lipid peroxidation in rat cardiac membranes. Biochem Pharmacol 2000;59:1623–1628
Gould L, Shariff M, Zahir M, Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969;48:860–868
Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984;54:852–855
Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974;49:754–760
Ruiz-del-Arbol L, Urman J, Fernández J, González M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210–1218
Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005;42:439–447
Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol 1992;69:523–531
Braverman AC, Steiner MA, Picus D, White H. High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest 1995;107:1467–1469
Ginès P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839–1847
Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44:743–748
Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007;56:869–875
Rabie R, Cazzaniga M, Salerno F, Wong F. The effect of cirrhotic cardiomyopathy on the post-TIPS outcome of patients treated for complications of portal hypertension. [abstract]. Hepatology 2006;44(Suppl 1):444A
Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996;61:1180–1188
Sampathkumar P, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, et al. Post-liver transplantation myocardial dysfunction. Liver Transpl Surg 1998;4:399–403
Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004;10:1441–1453
Torregrosa M, Aguadé S, Dos L, Segura R, Gónzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005;42:68–74
Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol 2003;38:461–467
Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004;40:239–246
Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008;48:415–421
Pozzi M, Grassi G, Ratti L, Favini G, Dell’Oro R, Redaelli E, et al. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gastroenterol 2005;100:1110–1116
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709–717
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wong, F. Cirrhotic cardiomyopathy. Hepatol Int 3, 294–304 (2009). https://doi.org/10.1007/s12072-008-9109-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12072-008-9109-7